Adenosine A

Area of Science:

• Medicinal Chemistry
• Biophysics
• Pharmacology

Background:

• G protein-coupled receptor (GPCR) ligand binding affinity is traditionally measured using radio-ligand competition assays.
• 19F nuclear magnetic resonance (19F-NMR) spectroscopy is an emerging technique for small-molecule lead compound screening in drug discovery.
• Existing methods for measuring ligand binding affinity and screening compounds often involve different experimental conditions.

Purpose of the Study:

• To develop and validate a fluorine-containing probe molecule, FPPA, for binding studies with the A2A adenosine receptor (A2AAR).
• To establish a robust 1D 19F-NMR protocol for drug screening and affinity measurements.
• To demonstrate the utility of 19F-NMR with FPPA for discovering novel A2AAR-targeting drug candidates.

Main Methods:

• Structure-based design of a fluorine-containing probe molecule (FPPA) based on the A2AAR-V-2006 complex.
• Development of experimental conditions for 1D 19F-NMR measurements.
• Validation of the FPPA-based 19F-NMR protocol using known A2AAR ligands.

Main Results:

• A novel fluorine-containing probe molecule, FPPA, was successfully designed for A2AAR binding studies.
• A validated 1D 19F-NMR protocol using FPPA was established for drug screening and affinity measurements.
• The method demonstrated robustness in identifying known A2AAR ligands.

Conclusions:

• 19F-NMR spectroscopy with the FPPA probe is a viable and robust alternative to traditional radio-ligand assays for A2AAR ligand discovery.
• This approach facilitates the screening of drug candidates and expands the library of potential A2AAR-targeting therapeutics.
• The methodology holds promise for discovering ligands with novel core structures.